PT  - JOURNAL ARTICLE
AU  - Zhao, Tong
AU  - Yang, Qize
AU  - Feuerbacher, Joshua F.
AU  - Yu, Bizhu
AU  - Brinkmann, Christian
AU  - Cheng, Sulin
AU  - Bloch, Wilhelm
AU  - Schumann, Moritz
TI  - Effects of exercise, metformin, and their combination on glucose metabolism in individuals with impaired glycemic control: A systematic review and network meta-analysis
AID  - 10.1101/2024.01.22.24301604
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.22.24301604
4099  - http://medrxiv.org/content/early/2024/01/23/2024.01.22.24301604.short
4100  - http://medrxiv.org/content/early/2024/01/23/2024.01.22.24301604.full
AB  - Objective To compare the efficacy of exercise, metformin, and their combination on glucose metabolism in individuals with prediabetes and type 2 diabetes mellitus (T2DM), and rank these treatments by exercise modality and metformin dosage.Design Systematic review and network meta-analysis.Data sources Embase, Web of Science, PubMed/MEDLINE, and SPORTDiscus were searched until February 2023.Eligibility criteria for selecting studies Randomized controlled trials (RCTs) of exercise, metformin, or their combined treatments in individuals with prediabetes or T2DM were included.Analyses We estimated pooled mean difference (MD) with 95% confidence intervals (CI) for five glucose metabolism variables (i.e., hemoglobin A1c [HbA1c], 2-h glucose during oral glucose tolerance test [OGTT], fasting glucose, fasting insulin, and homeostasis model assessment of insulin resistance [HOMA-IR]) via a random effect model. Subgroup analyses were conducted for prediabetes and T2DM populations.Results We identified 15,872 eligible articles and finally included 375 articles with 378 RCTs, comprising 30,884 participants. When all individuals were pooled, metformin had greater effects than exercise in improving HbA1c (MD −0.65 95% CI [−0.77 to −0.53] vs −0.38 [−0.45 to −0.32] %), 2-h glucose during OGTT (−1.16 [−1.67 to −0.65] vs −0.76 [−1.15 to −0.37]), fasting glucose (−0.99 [−1.14 to −0.83] vs −0.57 [−0.65 to −0.48] mmol/L), and fasting insulin (−2.28 [−3.03 to −1.53] vs −1.47 [−1.85 to −1.09] μU/mL), but not in HOMA-IR (−0.36 [−0.77 to 0.04] vs −0.73 [−0.90 to −0.57]). A similar pattern was observed for the subgroup of T2DM patients; however, in prediabetes, exercise showed better efficacy than metformin in HbA1c (−0.17 [−0.23 to −0.11] vs −0.09 [−0.20 to 0.01] %) and 2-h glucose (−0.68 [−1.01 to −0.35] vs −0.04 [−0.51 to 0.43] mmol/L). Exercise + metformin showed a greater efficacy than exercise alone in improving HbA1c (−0.79 [−1.27 to −0.30] %) and fasting glucose (−0.76 [−1.25 to −0.26] mmol/L) when all individuals were pooled. Considering exercise modalities, aerobic interval exercise was most efficient in improving fasting glucose (−0.82 [−1.06 to −0.59] mmol/L), HbA1c (−0.61 [−0.77 to −0.44] %), fasting insulin (−2.22 [−3.34 to −1.10] μU/mL), and HOMA-IR (−0.95 [−1.39 to −0.51]). The confidence in evidence was mostly low or very low.Conclusion The use of exercise, metformin, and their combination are all effective in improving glucose metabolism in individuals with impaired glycemic control, such as prediabetes or T2DM, but the efficacy varies in the five outcome parameters (i.e., HbA1c, OGTT 2-h glucose, fasting glucose, fasting insulin, and HOMA-IR). The efficacy was modified by exercise modality, metformin dosage, and severity of impaired glycemic control. Future clinical trials may further investigate the specific components of the interactive effects of exercise and metformin, such as the timing of exercise and metformin administration, the drug delivery method as well as the effect of additional exercise variables (e.g., exercise frequency and volume).PROSPERO registration number: CRD42023400622.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Chinese Scholarship Council (CSC, no. 202206230079).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe full dataset is available on request by contacting the corresponding author.